





A



B



Supplementary Figure S1. Box showing CMR characteristics of TAPSE/PASP and TAPSE tertiles. Shown are values for (A) RVEDVI and (B) LVEDVI divided according to TAPSE/PASP and TAPSE tertiles. Boxes represent median with IQR. ns, not significant, ** $p < 0.01$, *** $p < 0.001$.



A

B

Supplementary Figure S2. Box and scatter plots showing CMR characteristics of TAPSE tertiles. Shown are values for T1 relaxation times in (A) T1 lower RVIP and (B) T1 upper RVIP divided according to TAPSE tertiles. Boxes represent median with IQR. ns, not significant, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Supplementary Table S1. Clinical characteristics of TAPSE/PASP tertiles.

	TAPSE/PASP low <0.38 mm/mmHg	TAPSE/PASP middle 0.38–0.63 mm/mmHg	TAPSE/PASP High >0.63 mm/mmHg	p-Value
	n = 37	n = 36	n = 38	
Age, y, median (IQR)	70 (58–76)	69 (63–77)	67 (59–74)	0.69
Female sex, n, (%)	10 (27)	10 (28)	12 (32)	0.90
BMI, kg/m ² , mean (± SD)	27 ± 4	28 ± 5	27 ± 4	0.46
BSA, m ² , mean (± SD)	1.96 ± 0.22	2.03 ± 0.25	1.99 ± 0.18	0.51
Cardiovascular risk factors				
Hypertension, n, (%)	26 (70)	28 (82)	29 (76)	0.48
Diabetes, n, (%)	14 (38)	12 (35)	9 (24)	0.36
Insulin, n, (%)	2 (5)	4 (11)	4 (11)	0.71
Dyslipidemia, n, (%)	21 (58)	22 (67)	16 (44)	0.19
Clinical history				
Chronic pulmonary disease, n, (%)	4 (11)	7 (20)	6 (16)	0.61
CAD, n, (%)	23 (62)	21 (58)	23 (61)	0.97
Prior MI, n, (%)	12 (34)	10 (30)	15 (42)	0.64
Prior PCI, n, (%)	15 (41)	11 (33)	15 (39)	0.80
Prior CABG, n, (%)	6 (17)	11 (31)	4 (11)	0.09
Prior stroke/TIA, n, (%)	8 (22)	3 (9)	6 (16)	0.29
Peripheral artery disease, n, (%)	5 (14)	3 (9)	2 (5)	0.46
Symptoms				
NYHA ≥ 3, n, (%)	16 (53)	18 (58)	8 (33)	0.05
Syncope, n, (%)	2 (6)	4 (11)	2 (5)	0.65
Prior cardiac decompensation, n, (%)	12 (60)	8 (62)	6 (43)	0.61
Echocardiographic findings				
LVEF, %, median (IQR)	28 (25–40)	35 (28–50)	50 (35–55)	0.001
LVEF < 35 %, n, (%)	23 (62)	14 (41)	8 (24)	0.002
LVEDd, mm, mean (± SD)	58 ± 9	56 ± 9	54 ± 10	0.30
LA, mm, median (IQR)	44 (43–48)	41 (38–45)	40 (37–44)	0.008
IVSd, mm, median (IQR)	10 (9–12)	10 (9–11)	10 (9–12)	0.83
LVPWd, mm, median (IQR)	10 (10–12)	10 (8–11)	10 (9–11)	0.33
RVEDd, mm, median (IQR)	39 (35–44)	33 (30–38)	34 (31–37)	0.002
TAPSE, mm, mean (± SD)	14 ± 4	18 ± 3	22 ± 3	<0.001
PASP, mmHg, median (IQR)	49 (42–55)	40 (34–45)	28 (25–33)	<0.001
TAPSE/PASP, mm/mmHg, median (IQR)	0.28 (0.22–0.34)	0.46 (0.42–0.53)	0.74 (0.66–0.81)	<0.001
AS ≥/≤ II, n, (%)	3 (9)	0 (0)	0 (0)	0.06
MI ≥/≤ II, n, (%)	9 (26)	6 (18)	2 (5)	0.047
Biomarker				
Creatinine, mmol/L, median (IQR)	1.14 (0.86–1.44)	0.9 (0.79–1.27)	0.84 (0.7–1.02)	0.01
eGFR, ml/min/1.73 m ² , mean (± SD)	72 ± 28	80 ± 26	89 ± 29	0.08
NT-proBNP, pg/ml, median (IQR)	5829 (2084–9318)	1933 (807–3950)	542 (341–1376)	<0.001
MRI findings				
HF, 1/min, median (IQR)	71 (65–86)	70 (66–83)	70 (60–74)	0.26
LVEF, %, median (IQR)	27 (20–38)	30 (24–50)	47 (31–59)	0.001
LVEDV, ml, median (IQR)	246 (186–343)	230 (162–328)	177 (162–221)	0.01
LVEDVI, ml/m ² , median (IQR)	130 (99–168)	114 (86–152)	92 (80–109)	0.004
LVESV, ml, median (IQR)	172 (120–262)	158 (90–235)	102 (74–150)	0.003
LVESVI, ml/m ² , median (IQR)	90 (65–131)	82 (46–111)	51 (36–75)	0.001
LA area, m ² , mean (± SD)	31 ± 7	28 ± 9	26 ± 7	0.02
RVEF, %, median (IQR)	32 (19–40)	44 (30–50)	50 (42–58)	<0.001
RVEDV, ml, median (IQR)	192 (148–248)	170 (141–187)	141 (115–162)	<0.001
RVEDVI, ml/m ² , median (IQR)	104 (77–130)	77 (64–95)	73 (60–80)	<0.001
RV ESVI, ml/m ² , median (IQR)	66 (52–99)	47 (33–60)	34 (26–44)	<0.001
RV ESV, ml, median (IQR), ml, median (IQR)	128 (92.5–188.25)	97.5 (71–137.75)	70 (55–92)	<0.001
RV SV, ml, median (IQR)	61.5 (47.25–78)	58.5 (49–81.75)	68 (53.5–77.5)	0.72
RA area, m ² , median (IQR)	29 (24–36)	25 (24–30)	25 (23–29)	0.10
CI, l/min*m ² , median (IQR)	2.7 (2.1–3.2)	2.5 (2.2–2.8)	2.6 (2.1–3.2)	0.74
LV longitudinal Strain LAX global, %, median (IQR)	-8 (-11; -5)	-8 (-14; -7)	-14 (-19; -10)	0.001
RV longitudinal Strain LAX global, %, median (IQR)	-15 (-19; -8)	-16 (-20; -8)	-25 (-26; -24)	<0.001
T1 time septal, s, median (IQR)	1178 (1150–1202)	1158 (1121–1190)	1144 (1126–1183)	0.03
T1 time upper RVIP, s, median (IQR)	1170 (1120–1219)	1136 (1105–1199)	1117 (1073–1130)	<0.001

T1 time lower RVIP, s, median (IQR)	1208 (1174–1259)	1172 (1131–1226)	1192 (1142–1225)	0.001
-------------------------------------	------------------	------------------	------------------	-------

Supplementary Table S2. Multivariable regression analysis of predictors of 10-years mortality.

Model 1:			
Variable	<i>p</i>-value	Odds Ratio	95% CI
PASP	0.21	1.01	0.99–1.04
LVEDd	0.01	1.06	1.01–1.11
LVEF	0.17	0.97	0.93–1.01
eGFR	0.11	0.99	0.98–1.00
Diabetes	0.13	1.66	0.86–3.19
Prior PCI	0.01	2.22	1.20–4.13
Age	0.08	1.03	0.99–1.07
Model 2:			
Variable	<i>p</i> value	Odds Ratio	95% CI
TAPSE/PASP	0.02	0.12	0.02–0.71
LVEDd	0.02	1.05	1.01–1.10
LVEF	0.48	0.98	0.94–1.03
eGFR	0.05	0.99	0.98–1.01
Diabetes	0.11	1.71	0.89–3.28
Prior PCI	0.01	2.24	1.21–4.16